Trial
NCT07551544
ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer
Phase IIIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
ImmunityBio, Inc.
Collaborators
—
Condition
NMIBC
Intervention
BCG (50 mg) plus ANKTIVA (400 µg)
Why stopped
Sponsor decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-19